Silencing HMGCS2 and PPARα inhibits NOX activity by reducing ketone body production and the metabolic burden of fatty acids. This results in a decrease in ROS production, alleviates OS, and ultimately mitigates myocardial injury and dysfunction in DCM. This evidence concerns the gene PPARA and familial dilated cardiomyopathy.